Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

475
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
475
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

400
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
400
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.9K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.9K
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
Aneurysm IV: Nursing Management01:22

Aneurysm IV: Nursing Management

607
Vigilant monitoring for aneurysm rupture is essential for patients undergoing aortic surgery.Preoperative Nursing ManagementContinuously monitor the patient for manifestations of aneurysm rupture, such as pallor, weakness, tachycardia, hypotension, abdominal, back, groin, or periumbilical pain, changes in consciousness, and a pulsating abdominal mass. Regularly assess the patient's peripheral pulses.Instruct the patient to consume a clear liquid diet the day before surgery and administer...
607

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Tolerance of povidone-iodine in patients treated with intravitreal injection, about 619 patients].

Journal francais d'ophtalmologie·2026
Same author

[Role of ultrasound in the management of pilomatrixomas].

Journal francais d'ophtalmologie·2025
Same author

[National protocol for diagnosis and treatment of Coats disease: Summary for attending and primary care physicians].

Journal francais d'ophtalmologie·2025
Same author

When ointment slips up: The vaseline bubble and the case for "less is more" in cataract surgery.

Journal francais d'ophtalmologie·2025
Same author

[Premium IOL's in glaucoma patients: Guidelines from the French Glaucoma Society (SFG) and the Society of the French Intraocular Lens and Refractive Surgery Association].

Journal francais d'ophtalmologie·2025
Same author

[Postoperative bacterial endophthalmitis: Differential diagnosis and confirmation].

Journal francais d'ophtalmologie·2024

Related Experiment Video

Updated: Apr 18, 2026

Implantation Protocol of the Foldable Capsular Vitreous Body for Complex Vitreoretinal Surgery
04:36

Implantation Protocol of the Foldable Capsular Vitreous Body for Complex Vitreoretinal Surgery

Published on: April 14, 2026

53

[Managing antithrombotic therapy in vitreoretinal surgery].

M Gallice1, F Rouberol2, P Albaladejo3

  • 1Clinique universitaire d'ophtalmologie, CHU de Grenoble, boulevard de la Chantourne, 38700 La Tronche, France; Université Joseph-Fourier, 621, avenue Centrale, 38041 Saint-Martin-d'Hères, France.

Journal Francais D'Ophtalmologie
|January 12, 2015
PubMed
Summary

For patients undergoing vitreoretinal surgery, continuing single antiplatelet therapy (like aspirin) appears safe. However, risks of dual antiplatelet therapy and new anticoagulants require further study.

Keywords:
Antiagrégant plaquettaireAnticoagulantAnticoagulation therapyAntiplatelet therapyChirurgie vitréorétinienneHémorragie périopératoirePerioperative bleedingVitreoretinal surgery

More Related Videos

A Step by Step Protocol for Subretinal Surgery in Rabbits
12:31

A Step by Step Protocol for Subretinal Surgery in Rabbits

Published on: September 13, 2016

16.2K
Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases
11:20

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases

Published on: June 14, 2021

4.5K

Related Experiment Videos

Last Updated: Apr 18, 2026

Implantation Protocol of the Foldable Capsular Vitreous Body for Complex Vitreoretinal Surgery
04:36

Implantation Protocol of the Foldable Capsular Vitreous Body for Complex Vitreoretinal Surgery

Published on: April 14, 2026

53
A Step by Step Protocol for Subretinal Surgery in Rabbits
12:31

A Step by Step Protocol for Subretinal Surgery in Rabbits

Published on: September 13, 2016

16.2K
Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases
11:20

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases

Published on: June 14, 2021

4.5K

Area of Science:

  • Ophthalmology
  • Cardiology
  • Pharmacology

Context:

  • Increasing number of patients on antithrombotic therapy.
  • Management challenges in perioperative antithrombotic care for vitreoretinal surgery.
  • Lack of consensus on antithrombotic drug management.

Purpose:

  • To review current literature on managing antithrombotic therapy in patients undergoing vitreoretinal surgery.
  • To assess the risks of continuing antiplatelet and anticoagulant therapies versus the risks of thromboembolism.
  • To identify gaps in knowledge regarding newer antithrombotic agents.

Summary:

  • Continuing single antiplatelet therapy (acetylsalicylic acid, clopidogrel) is generally considered safe for vitreoretinal surgery.
  • An International Normalized Ratio (INR) below 3 may not increase perioperative ocular bleeding risk for anticoagulant users.
  • The safety of dual antiplatelet therapy and new oral anticoagulants (dabigatran, rivaroxaban, apixaban) in this context is not well-established.

Impact:

  • Informs clinical decision-making for perioperative antithrombotic management in ophthalmology.
  • Highlights the need for further research into newer antithrombotic agents and dual antiplatelet regimens.
  • Aims to optimize patient safety by balancing bleeding and thrombotic risks.